Abbott: Renal Insufficiency trials

The registry lists 11 Renal Insufficiency studies with Abbott as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 2 1Phase 3 4Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• XIENCE 28 USA StudyCompletedNCT03815175Not applicableResults posted
• XIENCE 28 Global StudyCompletedNCT03355742Not applicableResults posted
• Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary HyperparathyroidismCompletedNCT01081665Results posted
• Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial DoseCompletedNCT00891813Phase 4Results posted
• The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5TerminatedNCT00616902Phase 3Results posted
• Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart FailureTerminatedNCT00744341Phase 2
• Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal FunctionTerminatedNCT00568009
• Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on HemodialysisCompletedNCT00091481Phase 4
• Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)CompletedNCT00048516Phase 3
• Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)CompletedNCT00048451Phase 3
• Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)CompletedNCT00048438Phase 3